Publicacións en colaboración con investigadores/as de University of Missouri–Kansas City (2)

2021

  1. Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

    Cardiovascular Diabetology, Vol. 20, Núm. 1

2020

  1. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

    The Lancet Diabetes and Endocrinology, Vol. 8, Núm. 7, pp. 606-615